Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva Sells 860 Shares
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) SVP Paul M. Silva sold 860 shares of the business’s stock in a transaction on Monday, January 13th. The stock was sold at an average price of $229.38, for a total value of $197,266.80. Following the completion of the sale, the senior vice president now directly owns 18,619 shares in the company, valued at $4,270,826.22. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
NASDAQ VRTX opened at $234.15 on Thursday. The firm has a market cap of $59.08 billion, a price-to-earnings ratio of 82.74, a price-to-earnings-growth ratio of 1.33 and a beta of 1.47. The company has a quick ratio of 3.32, a current ratio of 3.44 and a debt-to-equity ratio of 0.12. The business has a 50-day moving average price of $221.97 and a 200-day moving average price of $192.65. Vertex Pharmaceuticals Incorporated has a twelve month low of $163.68 and a twelve month high of $234.33.
Vertex Pharmaceuticals (NASDAQ:VRTX) last announced its quarterly earnings results on Wednesday, October 30th. The pharmaceutical company reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $0.87 by $0.36. Vertex Pharmaceuticals had a return on equity of 20.33% and a net margin of 59.24%. The company had revenue of $949.83 million during the quarter, compared to analyst estimates of $942.90 million. During the same period in the prior year, the company earned $1.09 earnings per share. The firm’s revenue was up 21.1% on a year-over-year basis. Research analysts expect that Vertex Pharmaceuticals Incorporated will post 3.72 EPS for the current fiscal year.
Several equities research analysts have commented on the company. Raymond James downgraded Vertex Pharmaceuticals from an “outperform” rating to a “market perform” rating in a report on Thursday, January 2nd. Maxim Group reissued a “hold” rating on shares of Vertex Pharmaceuticals in a report on Friday, November 1st. BMO Capital Markets boosted their target price on Vertex Pharmaceuticals from to in a report on Thursday, January 9th. Argus boosted their target price on Vertex Pharmaceuticals to $248.00 and gave the stock a “buy” rating in a report on Monday, December 16th. Finally, Citigroup boosted their target price on Vertex Pharmaceuticals from $205.00 to $225.00 and gave the stock a “buy” rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and twenty have given a buy rating to the stock. Vertex Pharmaceuticals currently has a consensus rating of “Buy” and a consensus target price of $228.54.
Vertex Pharmaceuticals Company Profile
Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene.
See Also: What is Depreciation?
Receive News & Ratings for Vertex Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vertex Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.